Professor Lars Lannfelt, awarded the CTAD Lifetime Achievement Award in recognition for his pioneering work in Alzheimer's Disease
BioArctic AB announced that its co-founder, Professor Lars Lannfelt, received the Lifetime Achievement Award in Alzheimer's Disease Therapeutic Research at the CTAD congress in Madrid. The award recognizes his pioneering work in Alzheimer's disease research and drug development, particularly his contributions leading to lecanemab, a disease-modifying treatment for early Alzheimer's approved in multiple countries including the U.S., Japan, and China. Lannfelt founded BioArctic in 2003 with Pär Gellerfors to develop antibody treatments based on his discoveries about amyloid-beta protein's role in Alzheimer's disease. Lecanemab, developed in collaboration with Eisai, works by binding to and clearing specific forms of amyloid-beta from the brain.
BioArctic AB ha annunciato che il suo co-fondatore, il Professor Lars Lannfelt, ha ricevuto il Premio alla Carriera nella Ricerca Terapeutica sull'Alzheimer al congresso CTAD di Madrid. Questo premio riconosce il suo lavoro pionieristico nella ricerca sull'Alzheimer e nello sviluppo di farmaci, in particolare i suoi contributi che hanno portato a lecanemab, un trattamento modificante la malattia per l'Alzheimer precoce approvato in diversi paesi, tra cui USA, Giappone e Cina. Lannfelt ha fondato BioArctic nel 2003 insieme a Pär Gellerfors per sviluppare trattamenti a base di anticorpi basati sulle sue scoperte riguardo al ruolo della proteina amiloide-beta nella malattia di Alzheimer. Lecanemab, sviluppato in collaborazione con Eisai, agisce legandosi e rimuovendo specifiche forme di amiloide-beta dal cervello.
BioArctic AB anunció que su cofundador, el Profesor Lars Lannfelt, recibió el Premio a la Trayectoria en la Investigación Terapéutica del Alzheimer en el congreso CTAD en Madrid. Este premio reconoce su trabajo pionero en la investigación sobre la enfermedad de Alzheimer y el desarrollo de medicamentos, específicamente sus contribuciones que llevaron a lecanemab, un tratamiento modificador de la enfermedad para el Alzheimer temprano aprobado en múltiples países, incluidos EE. UU., Japón y China. Lannfelt fundó BioArctic en 2003 junto a Pär Gellerfors para desarrollar tratamientos con anticuerpos basados en sus descubrimientos sobre el papel de la proteína amiloide-beta en la enfermedad de Alzheimer. Lecanemab, desarrollado en colaboración con Eisai, actúa uniéndose y eliminando formas específicas de amiloide-beta del cerebro.
BioArctic AB는 공동 창립자인 Lars Lannfelt 교수가 마드리드에서 열린 CTAD 회의에서 알츠하이머병 치료 연구 평생 공로상을 수상했다고 발표했습니다. 이 상은 알츠하이머병 연구 및 약물 개발에서 그의 선구적인 작업을 인정하며, 특히 미국, 일본 및 중국을 포함한 여러 국가에서 승인된 조기 알츠하이머병 치료제인 레카네맙과 관련된 그의 기여를 강조합니다. Lannfelt는 Pär Gellerfors와 함께 2003년에 BioArctic를 설립하여 알츠하이머병에서 아밀로이드 베타 단백질의 역할에 대한 그의 발견을 기반으로 항체 치료제를 개발했습니다. 레카네맙은 Eisai와 협력하여 개발되었으며, 뇌에서 특정 형태의 아밀로이드 베타를 결합하고 제거하여 작용합니다.
BioArctic AB a annoncé que son co-fondateur, le Professeur Lars Lannfelt, a reçu le Prix d'Excellence pour la Recherche Thérapeutique sur la Maladie d'Alzheimer lors du congrès CTAD à Madrid. Ce prix reconnaît son travail pionnier dans la recherche sur la maladie d'Alzheimer et le développement de médicaments, en particulier ses contributions ayant conduit à lecanemab, un traitement modifiant la maladie pour le stade précoce d'Alzheimer, approuvé dans plusieurs pays, dont les États-Unis, le Japon et la Chine. Lannfelt a fondé BioArctic en 2003 avec Pär Gellerfors pour développer des traitements par anticorps basés sur ses découvertes concernant le rôle de la protéine amyloïde-bêta dans la maladie d'Alzheimer. Lecanemab, développé en collaboration avec Eisai, agit en se liant à des formes spécifiques d'amyloïde-bêta et en les éliminant du cerveau.
BioArctic AB gab bekannt, dass sein Mitbegründer, Professor Lars Lannfelt, auf dem CTAD-Kongress in Madrid den Lifetime Achievement Award in Alzheimerforschung erhalten hat. Der Preis würdigt seine wegweisende Arbeit in der Forschung zur Alzheimer-Krankheit und bei der Arzneimittelentwicklung, insbesondere seine Beiträge, die zur Lecanemab führten, einer krankheitsmodifizierenden Therapie für frühe Alzheimer, die in mehreren Ländern, einschließlich der USA, Japan und China, zugelassen ist. Lannfelt gründete 2003 zusammen mit Pär Gellerfors BioArctic, um Antikörperbehandlungen basierend auf seinen Entdeckungen über die Rolle des Amyloid-Beta-Proteins bei der Alzheimer-Krankheit zu entwickeln. Lecanemab, das in Zusammenarbeit mit Eisai entwickelt wurde, wirkt, indem es sich an spezifische Formen von Amyloid-Beta im Gehirn bindet und diese entfernt.
- Lecanemab, developed by BioArctic, has received regulatory approval in major markets including U.S., Japan, and China
- The drug demonstrated meaningful benefits to patients in the phase 3 Clarity AD trial
- Recognition through prestigious award validates the company's scientific approach and leadership in Alzheimer's research
- None.
Professor Lannfelt's groundbreaking research has played a significant role in the scientific progress made in the field over decades, leading to the development of lecanemab, a disease-modifying treatment for early Alzheimer's disease approved in the
"The search for treatments to give hope and help patients and families affected by Alzheimer's disease is what has driven me throughout my scientific career," said Professor Lars Lannfelt. "This field or research is in the midst of a paradigm shift driven by the development of treatments such as lecanemab, which has demonstrated meaningful benefits to patients in the large phase 3 trial Clarity AD using gold standard endpoints. Coupled with the introduction of new diagnostic methods, I am convinced that within a number of years, we will not only be able to slow the progression of the disease, but eventually also stop the disease process entirely."
Professor Lars Lannfelt founded BioArctic together with Pär Gellerfors in 2003 to develop an antibody treatment based on Lannfelt's groundbreaking discoveries of the role of amyloid-beta protein in Alzheimer's disease. These discoveries are the basis for lecanemab, an antibody treatment developed in collaboration with the Japanese company Eisai. By binding to specific forms of amyloid-beta, which causes Alzheimer's disease, lecanemab helps to clear them from the brain, thereby altering the course of the disease.
The 17th annual CTAD international conference brings together 2,200 leading experts in
The information was released for public disclosure, through the agency of the contact persons below, on October 30, 2024, at 08.30 a.m. CET.
For further information, please contact:
Oskar Bosson, VP Communications and IR
E-mail: oskar.bosson@bioarctic.se
Phone: +46 70 410 71 80
About lecanemab
Lecanemab is the result of a strategic research collaboration between BioArctic and Eisai. Lecanemab is a humanized IgG1 (immunoglobulin gamma 1) monoclonal antibody targeting aggregated soluble and insoluble forms of amyloid beta (Aβ). Lecanemab is approved in the
About the collaboration between BioArctic and Eisai
Since 2005, BioArctic has a long-term collaboration with Eisai regarding the development and commercialization of drugs for the treatment of Alzheimer's disease. The most important agreements are the Development and Commercialization Agreement for the lecanemab antibody, which was signed 2007, and the Development and Commercialization agreement for the antibody LEQEMBI back-up for Alzheimer's disease, which was signed 2015. In 2014, Eisai and Biogen entered into a joint development and commercialization agreement for lecanemab. Eisai is responsible for the clinical development, application for market approval and commercialization of the products for Alzheimer's disease. BioArctic has the right to commercialize lecanemab in the Nordic region under certain conditions and is currently preparing for commercialization in the Nordics together with Eisai. BioArctic has no development costs for lecanemab in Alzheimer's disease and is entitled to payments in connection with regulatory approvals, and sales milestones as well as royalties on global sales.
About BioArctic AB
BioArctic AB (publ) is a Swedish research-based biopharma company focusing on disease-modifying treatments for neurodegenerative diseases, such as Alzheimer's disease, Parkinson's disease and ALS. BioArctic focuses on innovative treatments in areas with high unmet medical needs. The company was founded in 2003 based on innovative research from Uppsala University,
This information was brought to you by Cision http://news.cision.com
The following files are available for download:
Professor Lars Lannfelt, awarded the CTAD Lifetime Achievement Award in recognition for his pioneering work in Alzheimer's Disease |
View original content:https://www.prnewswire.com/news-releases/professor-lars-lannfelt-awarded-the-ctad-lifetime-achievement-award-in-recognition-for-his-pioneering-work-in-alzheimers-disease-302291249.html
SOURCE BioArctic
FAQ
What award did BioArctic's (BIOA) co-founder receive at CTAD 2024?
In which countries has BioArctic's (BIOA) lecanemab been approved?
How does BioArctic's (BIOA) lecanemab work in treating Alzheimer's disease?
